Search clinical trials for: D745, D150

Total 672 results

Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150 (CKD-383)

Type 2 Diabetes

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150

Diabetes type2

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Pharmacokinetics and Safety/Tolerability of CKD-379

Type II Diabetes Mellitus

Korea, Republic of
Chong Kun Dang Pharmaceutical

Active, not recruiting

Study to Evaluate the Safety and Pharmacokinetics of CKD-379

Type II Diabetes Mellitus

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.

Type2 Diabetes Mellitus

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029

Type 2 Diabetes

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Pharmacokinetics and Safety/Tolerability Profile of CKD-379

Type II Diabetes Mellitus

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378

Type II Diabetes

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

Type 2 Diabetes

Korea, Republic of
Chong Kun Dang Pharmaceutical

Recruiting

The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes

Type 2 Diabetes

Korea, Republic of
Chong Kun Dang Pharmaceutical

Unknown

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy Adults

Type 2 Diabetes Mellitus

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects (CKD-371)

Type II Diabetes Mellitus

Korea, Republic of
Sinocelltech Ltd.

Not yet recruiting

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years

COVID-19 | SARS-CoV-2 Infection
Chong Kun Dang Pharmaceutical

Completed

Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg

Type 2 Diabetes Mellitus

Korea, Republic of
ModernaTX, Inc.

Recruiting

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

Glycogen Storage Disease

United States, Canada
Gilead Sciences

Terminated

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

Cystic Fibrosis

France, Germany, Spain, United Kingdom, Australia
Chong Kun Dang Pharmaceutical

Not yet recruiting

Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions

Cardiovascular Diseases

Korea, Republic of
Chong Kun Dang Pharmaceutical

Not yet recruiting

Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions

Cardiovascular Diseases

Korea, Republic of
Gilead Sciences

Terminated

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

Spain, United Kingdom, United States, France, Italy, Germany, New Zealand, Australia, Poland, South Africa, Hungary, Canada, Czechia
Ono Pharma USA Inc
Ono Pharmaceutical Co. Ltd

Completed

An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Healthy | Hepatic Impairment

United States
Gilead Sciences

Terminated

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Australia, France, Poland, Ukraine, Switzerland, Romania, Canada, Netherlands, Korea, Republic of, Belgium, Russian Federation, Taiwan, New Zealand, Hungary, United Kingdom, Bulgaria, Latvia, Czechia, Slovakia, Italy and more
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)

Type 2 Diabetes Mellitus

Korea, Republic of
Gilead Sciences

Completed

Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults

Ulcerative Colitis

New Zealand
EIP Pharma Inc

Completed

A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Netherlands
EIP Pharma Inc

Completed

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Alzheimer's Disease

United States
Gilead Sciences

Completed

Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Hungary, Czech Republic
Jiangsu Atom Bioscience and Pharmaceutical Co.,...

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers (ABP-745)

Gout

United States
Pinta Biotherapeutics

Completed

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

End Stage Renal Disease | Kidney Disease | Protein Energy Wasting

United States
University Hospital, Toulouse
Fondation Plan Alzheimer

Completed

Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients (VIP)

Alzheimer Disease

France
EIP Pharma Inc
Voisin Consulting, Inc.

Terminated

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

Huntington Disease

United Kingdom
Lesaffre International
NIZO Food Research

Completed

BSCU1 and Immune Function

General Population

Netherlands
EIP Pharma Inc
Amsterdam UMC, location VUmc; Worldwide Clinical Trials

Completed

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease (REVERSE-SD)

Alzheimer Disease

United States, Netherlands, United Kingdom, Czechia, Denmark
Amgen

Withdrawn

AMG 745 in Subjects With Age-associated Muscle Loss

Age-associated Muscle Loss
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)

Cardiovascular Diseases

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
EIP Pharma Inc
National Institute on Aging (NIA); Worldwide Clinical Trials; CervoMed, Inc

Recruiting

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States, United Kingdom, Netherlands
Chong Kun Dang Pharmaceutical

Completed

A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions

Type2Diabetes

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Chong Kun Dang Pharmaceutical

Unknown

Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions

Cardiovascular Diseases

Korea, Republic of
Hospital de Clinicas de Porto Alegre
Federal University of Rio Grande do Sul

Unknown

Exercise Dose-response for Diabetes in the Elderly (EDDIE)

Type2 Diabetes

Brazil
Chong Kun Dang Pharmaceutical

Unknown

Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

T2DM (Type 2 Diabetes Mellitus)

Korea, Republic of
Gilead Sciences

Completed

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects

Healthy
Hospital General Universitario Elche

Unknown

RYGB AL 150cm BPL 100cm vs RYGB AL 100cc BPL 150cm

Weight Loss
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)

Cardiovascular Diseases

Korea, Republic of
Centre d'Investigation Clinique et Technologique...

Completed

Optimizing Communication During Ventilation (PHONOVNI)

Respiratory Failure | Neuromuscular Disorder

France
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Netherlands, Canada, Hungary, Moldova, Republic of, Romania
Tecnoquimicas

Unknown

Bioequivalence Study of Levothyroxine Sodium Tablets 150 mcg

Healthy

Colombia
Boehringer Ingelheim

Completed

Bioavailability, Pharmacokinetics and Safety of ESR 1150 CL in Healthy Adult Male Volunteers

Healthy
Gilead Sciences

Completed

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Spain, United States, Hungary, United Kingdom, Italy, France, Poland, Australia, Belgium

3

Subscribe